Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mylan NV (NASDAQ:MYL)

45.62
Delayed Data
As of Aug 23
 -2.28 / -4.76%
Today’s Change
37.59
Today|||52-Week Range
55.51
-15.63%
Year-to-Date
BTIG's Chiang Explains on CNBC Why He's Sticking With Mylan (MYL)
Aug 23 / TheStreet.com - Paid Partner Content
Mylan (MYL) Stock Slides on EpiPen Price Criticism
Aug 19 / TheStreet.com - Paid Partner Content
Mylan (MYL) Stock Slides, Citigroup: EpiPen Scrutiny Could Drive Multiples Down
Aug 23 / TheStreet.com - Paid Partner Content
Mylan Beats on Q2 Earnings, Revenues Miss, Keeps '16 View
Aug 10 / Zacks.com - Paid Partner Content
A Backlash Materializes Against Soaring EpiPen Prices
Aug 23 / TheStreet.com - Paid Partner Content
Company News for August 10, 2016
Aug 10 / Zacks.com - Paid Partner Content
U.S. Senator Grassley Requests EpiPen Pricing Explanation From Mylan (MYL)
Aug 22 / TheStreet.com - Paid Partner Content
Higher Specialty Drug Sales Help Mylan N.V. in Q2
Aug 10 / MotleyFool.com - Paid Partner Content
Swiss Generics Manufacturer Has Strong 1st Half of Year
Aug 22 / GuruFocus News - Paid Partner Content
Drugmakers hooked on $10bn opioid habit
Aug 10 / FT.com - Paid Partner Content